close
Add to watchlist
Medivation Inc (MDVN)
Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. Medivation, Inc. was founded in 2003 and is based in San Francisco, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 70.55 |
| Volume | 901555 |
| Volume Avg | 779477 |
| 52 Week High | 76.65 |
| 52 Week Low | 14.32 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -1.11 |
| EPS change Q/Q | -118.18% |
| EPS change Q/Q Yr ago | -52.94% |
| EPS change Q/Q next Q est | -46.67% |
| EPS change Y/Y | -177.78% |
| REV change Q/Q | -11.45% |
| REV change Q/Q Yr ago | -6.37% |
| EPS next Q est | -0.45 |
| EPS next Y est | -0.79 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |